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It has been well documented that β-amyloid (Aβ) peptide accumulation and aggregation in
the brain plays a crucial role in the pathophysiology of Alzheimer’s disease (AD). However,
a new orientation of the amyloid cascade hypothesis has evidenced that soluble forms
of the peptide (sAβ) are involved in Aβ-induced cognitive impairment and cause rapid
disruption of the synaptic mechanisms underlying memory. The primary aim of this study
was to elucidate the effects of sAβ, acutely injected intracerebrally (i.c.v., 4 µM), on the
short term and long term memory of young adult male rats, by using the novel object
recognition task. Glutamatergic receptors have been proposed as mediating the effect
of Aβ on synaptic plasticity and memory. Thus, we also investigated the effects of sAβ
on prefrontal cortex (PFC) glutamate release and the specific contribution of N-methyl-D-
aspartate (NMDA) receptor modulation to the effects of sAβ administration on the cognitive
parameters evaluated. We found that a single i.c.v. injection of sAβ 2 h before testing
did not alter the ability of rats to differentiate between a familiar and a novel object, in
a short term memory test, while it was able to negatively affect consolidation/retrieval
of long term memory. Moreover, a significant increase of glutamate levels was found in
PFC of rats treated with the peptide 2 h earlier. Interestingly, memory deficit induced by
sAβ was reversed by a NMDA-receptor antagonist, memantine (5 mg/kg i.p), administered
immediately after the familiarization trial (T1). On the contrary, memantine administered
30 min before T1 trial, was not able to rescue long term memory impairment. Taken
together, our results suggest that an acute i.c.v. injection of sAβ peptide interferes with the
consolidation/retrieval of long term memory. Moreover, such sAβ-induced effect indicates
the involvement of glutamatergic system, proposing that NMDA receptor inhibition might
prevent or lead to the recovery of early cognitive impairment.
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INTRODUCTION
Extensive research on the neurotoxic role of beta amyloid (Aβ)
in its fibrillar form has demonstrated that it accumulates in
the brain as extracellular insoluble plaques around neurons
and glia (Kowalewski and Holtzman, 1999; Mucke and Selkoe,
2012). Later, this view changed when it was recognized that
in Alzheimer’s disease (AD) patients, cognitive impairment is
poorly correlated with counts of “senile plaques” in cerebral
gray matter either in patients (Blennow et al., 1996; Berg et al.,
1998; Giannakopoulos et al., 2003, 2009) or in animal mod-
els (Puoliväli et al., 2002; Christensen et al., 2008; Watanabe
et al., 2009; Zhang et al., 2012). More recently, in support
of this, the initial etiopathogenetic hypothesis has been ques-
tioned by the failure of several clinical trials testing drugs
targeting Aβ accumulation in the brain (Mangialasche et al.,
2010).
Instead, a new orientation of the amyloid cascade hypothesis
appeared and more recent studies suggested that a stronger inter-
relationship exists between the presence of soluble beta amyloid
(sAβ) and dementia severity. Soluble Aβ oligomers were recently
reported to be dramatically increased in the soluble fraction of
AD brain extracts (Sokolow et al., 2012), and they have been
found to correlate with disease progression or decline in synaptic
density in AD patients (Lue et al., 1999; McLean et al., 1999).
In this scenario, soluble oligomeric, globular and protofibrillar
amyloid species, rather than fibrils, could be considered the first
toxic species and are hypothesized to contribute to synaptic failure
and early cognitive loss in AD (Arendt, 2009). In this regard, the
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role of sAβ in the pathophysiology of AD still remains a matter
of intense research at present. Interestingly, impaired neuronal
functions have been directly attributed to soluble oligomeric
forms of Aβ, even before the appearance of overt signs of neu-
rotoxicity (Lesné et al., 2006; Haass and Selkoe, 2007). Moreover,
sAβ has been found to cause rapid disruption of the synaptic
mechanisms underlying memory. It has been demonstrated that
sAβ oligomers, directly extracted from the cerebral cortex of
subjects with AD, were able to disrupt the memory of a learned
behavior in normal rats (Shankar et al., 2008). However, very
few studies have focused on the investigation of the effects of
defined sequences of sAβ on memory. In this regard, transgenic
mice models of AD, although covering several aspects of the
disease, do not permit an accurate identification of Aβ species
responsible of memory loss, being the peptide expressed either
in soluble or insoluble forms in the brain. This characteristic does
not allow to determine which specific Aβ species is responsible
for the detrimental effects. On the other hand, peptide injection
in the rat’s brain might be considered as a valid alternative to
transgenic animals to evaluate the effects of an increase of sAβ
species in the brain without presence of plaques. Then, to date, the
comprehension of the specific role of sAβ on different temporal
forms of memory remains an urgent need. To further investigate
the specific effects of sAβ, we recently developed a simple and
reliable rat model of memory impairment induced by an acute
i.c.v. injection of sAβ1-42 (Trabace et al., 2007; Colaianna et al.,
2010). We demonstrated that sAβ significantly affected behavior
that rely on stressful conditions. In particular, sAβ-treated rats
were not able to retrieve the learned behavior, fear conditioned,
in a passive avoidance task (Morgese et al., 2014).
In order to evaluate if sAβ-treated rats may differently respond
to behavioral cognitive tasks that do not involve stressful situa-
tions, we used an animal paradigm that is not demanding for
the animals, but is based on the natural propensity of rats to
explore novel situations. A simple and reliable task widely used
for the investigation of memory is the one-trial novel object
recognition (NOR) test. This procedure typically consists of three
phases: habituation, familiarization, and finally the test phase.
Rats naturally tend to approach and to explore novel over familiar
objects. Such task relies on spontaneous animal behavior without
the need neither for positive reinforcers nor for stressor elements,
such as water or food deprivation, electric foot-shock or aversive
environments. In particular, the ability of recognizing a previously
presented stimulus varies according to the delay between the
familiarization and the test phase. Based on this, the NOR test is
very useful to study short-term and long-term memory (Ennaceur
and Delacour, 1988; Taglialatela et al., 2009). This is possible by
manipulating the amount of time rats must retain memory of
the sample objects presented during the familiarization phase. In
particular, short term memory is represented by the process that
maintains a representation of information for a short period of
time, and it is available for posterior use, while the long-term
memory requires stabilization to persist. This process implies
a reorganization of the already established memories, allowing
then incorporation of new information (Clarke et al., 2010). In
this regard, early studies carried out in senescence-accelerated-
prone 8 (SAMP8) mouse strain, presenting cognitive deficiencies
that could be related to the accumulation of amyloid aggre-
gates, have shown a functional alteration in the hippocampal-
prefrontal circuits which is related to the object recognition deficit
(Lopez-Ramos et al., 2012).
The current study was designed to address on which phase
of the memory process sAβ exerts its effects. We evaluated the
effects of sAβ, acutely injected intracerebrally, on the short term
and long term memory of young adult male rats. Since the
training-testing interval is extremely informative regarding the
mechanism of action underlying the type of memory impair-
ment, we chose two different experimental paradigms, especially
well-suited to study short term memory (1 min retention inter-
val, NOR1) and long term memory (24 h retention interval,
NOR2).
Literature data point out that soluble forms of the peptide, in
particular oligomers ranging from dimers and trimers to dode-
camers, are involved in Aβ-induced cognitive impairment and are
capable of blocking long-term potentiation (LTP) and the reversal
of long term depression (LTD; Lambert et al., 1998; Wilcox et al.,
2011). Moreover, in Aβ-based model of AD, it has been found
a predominant susceptibility of glutamatergic synapses (Canas
et al., 2014). In addition, a direct application of sAβ oligomers or
fragments to cultured hippocampal neurons was found to rapidly
trigger sustained calcium entry through N-methyl-D-aspartate
(NMDA) receptors that was prevented by antagonists of NMDA
receptors (Kelly and Ferreira, 2006; De Felice et al., 2007) and
to enhance NMDA-evoked cell firing rate (Molnár et al., 2004).
Moreover, fragments of Aβ have been shown to bind glycine
and glutamate recognition sites on NMDA receptors (Cowburn
et al., 1997). Therefore, a further aim of the present study was to
examine the effects of sAβ on glutamate release and the specific
contribution of NMDA receptor modulation to the cognitive
deficits associated with sAβ administration. To this end, we tested
the effects of NMDA receptor inhibition on memory disruption
in rats i.c.v. injected with sAβ.
MATERIALS AND METHODS
ANIMALS
All experiments were conducted in young male Wistar rats
(Harlan S. Pietro al Natisone, Udine, Italy) weighing 250–300 g.
They were group-housed at constant room temperature
(22 ± 1◦C) and relative humidity (55 ± 5%) under a 12-h
light/dark cycle (lights on from 7:00 AM to 7:00 PM) for at least
7 days before the experiments. Food and water were available
ad libitum. Procedures involving animals and their care were
conducted in conformity with the institutional guidelines in
compliance with national (D.L. 116/92) and international laws
and policies (EEC Council Directive 2010/63/EU; Guide for the
Care and Use of Laboratory Animals, U.S. National Research
Council, 1996). All efforts were made to minimize the number of
animals used and their suffering.
SURGERY
Surgery procedures were performed as previously described
(Colaianna et al., 2010). Briefly, rats were anesthetized with
3.6 ml/kg Equithesin intraperitoneally (i.p.; composition: 1.2 g
sodium pentobarbital; 5.3 g chloral hydrate; 2.7 g MgSO4; 49.5 ml
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propylene glycol; 12.5 ml ethanol and 58 ml distilled water) and
secured in a stereotaxic frame (David Kopf Instruments, Tujunga,
CA, USA). The skin was shaved, disinfected and cut with a sterile
scalpel to expose the skull in order to perform the procedures
described below.
SOLUBLE Aβ1-42 ADMINISTRATION
The sAβ peptide was obtained from Tocris (Bristol, UK). All
solutions were freshly prepared. Peptide was dissolved in sterile
double-distilled water (vehicle) at a concentration of 4 µM as
previously described (Colaianna et al., 2010). On the day of
surgery, bilateral 23 gauge guide cannulae were implanted using
the following coordinates relative to Bregma: AP =−0.5 mm, ML
= +1.2 mm, DV =−3.0 mm with the incisor bar set at−3.3 mm,
according to a stereotaxic atlas (Paxinos and Watson, 1998). The
day after surgery procedure, intraventricular injections were made
using injection needles (30-gauge stainless steel tubing; Cooper’s
Needles, Birmingham, UK) which extended an additional 0.2 mm
below the guide cannulae (total depth 3.2 mm). Soluble Aβ (5 µl)
was delivered through a 25 µl Hamilton microsyringe at 2 µl/min
infusion rate for duration of 2.5 min. Control rats were injected
with vehicle only, because reverse sAβ42-1, used in preliminary
experiments, had no effect on the measured parameters and was
indistinguishable from vehicle alone (unpublished observations).
The injection needle was left in place for additional 5 min to
prevent reflux of the solution. The injection placement of needle
track was verified at the time of dissection. All experimental
procedures were performed 2 h after i.c.v. administration (sham-
operated or sAβ-treated groups).
OTHER CHEMICALS
Memantine hydrochloride (3,5-dimethyl-1-adamantanamine
hydrochloride, 3,5-dimethylamantadine hydrochloride) was
purchased from Sigma-Aldrich Chemical Co. (Milan, Italy). It
was dissolved in 1 ml/kg of 0.9% NaCl (saline) and administered
intraperitoneally at a dose of 5 mg/kg.
NOVEL OBJECT RECOGNITION (NOR) TEST
During the NOR test rats were submitted to two habituation
sessions where they were allowed 5 min to explore the apparatus
(circular arena, 75 cm diameter).
The NOR1 test was performed according to Giustino et al.
(1996). Briefly, 24 h after last habituation, a session of two 3-min
trials separated by a 1-min intertrial interval (retention interval)
was carried out (Figure 1A).
The NOR2 test was performed according to Balducci et al.
(2010). Briefly, 24 h after last habituation, a session of two 10-min
trials separated by a 24 h intertrial interval (retention interval) was
carried out (Figure 1B). In both experimental conditions (NOR1
and NOR2), 2 h before the first trial (T1, training session), rats
received i.c.v injection of sAβ solution or vehicle. Then, animals
were exposed to two identical objects (white glasses or light
bulbs). During the second trial (T2, testing session), rats were
exposed to one familiar (F) object and the second was replaced by
a new object (N) differently shaped. In a different session using
the NOR2 protocol, memantine was administered i.p. (5 mg/kg)
30 min before or immediately after T1 trial.
In both protocols, during each trial, objects were placed in
an equidistant position between the center and the wall of the
arena. From rat to rat, the position of the two objects was coun-
terbalanced and randomly permuted during T2. At the beginning
of each trial, rats were placed near the center of the arena with
their heads oriented in the opposite direction to the objects.
Exploration of the objects was defined as sniffing or touching the
object with the nose. Turning around or sitting on the object was
not considered as exploration (Ennaceur and Delacour, 1988).
Object exploration was quantified as: exploratory activity, total
time spent exploring both objects during each trial (T1 and T2);
index of discrimination expressed as ratio between the net time
spent exploring the new (N−F) over the total exploration time
(N−F/N+F). Objects and arena were carefully cleaned between
each session to avoid olfactory confounding stimuli. Preliminary
tests showed that none of the objects used in our experiments
evoked innate preference.
MICRODIALYSIS PROCEDURE
Animals were deeply anesthetized as reported above and placed
on a stereotaxic apparatus (David Kopf Instruments, Tujunga,
CA). One horizontal custom-constructed microdialysis probe
(AN69 HospalS.p.A; 20 kDa cut-off, 6 mm length) was implanted
aiming at the prefrontal cortex (PFC). The coordinates, mea-
sured from the interaural line, were AP = +10.7 mm and
DV = +8.0 mm according to the atlas (Paxinos and Watson,
1998). The microdialysis probe was fixed to the skull with stainless
steel screws and methylacrylic cement. Twenty four hours after
surgery, the microdialysis probe was perfused with artificial CSF
solution (NaCl 145 mmol/L, KCl 2.7 mmol/L, CaCl2 2H2O 1.2
mmol/L, MgCl2 6H2O 1 mmol/L, Na2HPO4 2 mmol/L, pH
7.4) at a constant flow rate of 2 µl/min. Perfusates were col-
lected every 20 min into mini-vials. After a wash-out period
of 2 h, four samples were collected to determine the baseline
levels of glutamate (no more than 10% difference among four
consecutive samples). Glutamate concentrations were detected
and quantified by high performance liquid chromatography
(HPLC).
QUANTIFICATION OF GLUTAMATE BY HPLC
Glutamate concentrations were determined by HPLC using ODS-
3 column (150 × 4.6 mm, 3 µm; INERTSIL) with fluor
escence detection after derivatization with ophthalalde-
hyde/mercaptopropionic acid (emission length, 4.60 nm;
excitation length, 3.40 nm). The mobile phase gradient consisted
of 50 mM sodium acetate buffer, pH 6.95, with methanol
increasing linearly from 2 to 30% (v/v) over 40 min. The flow rate
was maintained by a pump (JASCO, Tokyo, Japan) at 0.5 ml/min.
Results were analyzed by Borwin software (version 1.50; Jasco)
and substrate concentration was expressed as µM.
STATISTICAL ANALYSIS
All statistical analyses were performed using Graph Pad®5.0 for
Windows. Data were tested for normality by the selection of
parametric and non-parametric tests. Data were analyzed by a
Two-way analysis of variance for repeated measures (Two-way
RM ANOVA) followed by a Bonferroni’s multiple comparison
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FIGURE 1 | Schematic representation of experimental procedure (A) NOR1 protocol according to Giustino et al. (1996); (B) NOR2 protocol according
to Balducci et al. (2010).
test or Student’s t-test, as required. Differences were considered
significant only when P-values were less than 0.05.
RESULTS
EFFECTS OF ACUTE I.C.V. INJECTION OF sAβ ON SHORT TERMMEMORY
(NOR1)
Our data showed that either sham- or sAβ-treated rats exhib-
ited normal performance in the NOR1 test, with a significant
difference in total time spent exploring the new object rather
than the familiar one during the test (Two-way RM ANOVA fol-
lowed by Bonferroni’s multiple comparisons test: Ft(1,15) = 41.54,
P < 0.0001; Figure 2A). Moreover, the preference between the
different objects (discrimination index) during testing did not
change significantly between experimental groups showing that
sAβ, injected 2 h before training, did not affect short term
memory for the familiar object (t-test: n.s.; Figure 2B). As shown
in Figure 2C, no statistical differences were found in total explo-
ration time, during both trials (T1 and T2), between sham and
sAβ-treated rats (t-test: n.s.).
EFFECTS OF ACUTE I.C.V. INJECTION OF sAβ ON LONG TERMMEMORY
(NOR2)
As shown in Figure 3A, sAβ-treated rats failed to acquire the
object recognition memory. Statistical analysis revealed a signif-
icant difference in exploratory activity between the experimental
groups (Two-way RM ANOVA: Ft(1,16) = 28.52, P < 0.0001). In
particular, sAβ-treated rats were not able to recognize the novel
object, while sham-operated animals preferentially explored the
novel rather than the familiar one (Bonferroni’s post hoc test:
P < 0.001). Accordingly, the discrimination index was signifi-
cantly lower than controls (t-test: P< 0.05; Figure 3B). No differ-
ences in total exploration time were found between experimental
groups (t-test: n.s.; Figure 3C).
EFFECTS OF MEMANTINE ON LONG TERMMEMORY IMPAIRMENT
INDUCED BY ACUTE I.C.V. INJECTION OF sAβ
To establish whether the memory deficit observed in the NOR2
protocol was dependent on glutamatergic modulation, rats were
treated with memantine (5 mg/kg i.p.) or vehicle immediately
after the 10 min training session (T1). Twenty-four hours later,
rats were subjected to the test phase, as described above. As
shown in Figure 4A, a clinically relevant dose of memantine was
able to prevent the long term memory impairment induced by
sAβ (Two-way RM ANOVA followed by Bonferroni’s multiple
comparisons test: Ft(1,14) = 23.34, P < 0.001). Then, while rats
injected with sAβ did not discriminate between the familiar and
the new object, the inhibition of NMDA receptors prevented
this memory deficit (t-test: n.s.; Figure 4B). No differences in
total exploration time were found between experimental groups
(Figure 4C).
Interestingly, when memantine was administered 30 min
before the familiarization phase (T1), sAβ-injected rats, tested
24 h later, remained cognitively impaired (Two-way RM
ANOVA followed by Bonferroni’s multiple comparisons test:
Ft(1,10) = 25.13, P < 0.001; Figure 5A). Accordingly, the discrimi-
nation index was significantly lower than control (t-test: P< 0.05;
Figure 5B). Total exploration time was not modified between
experimental groups (t-test: n.s.; Figure 5C). The treatment with
memantine alone did not affect memory.
EFFECTS OF ACUTE I.C.V. INJECTION OF sAβ ON GLUTAMATE LEVELS
Glutamate basal levels were measured in microdialysis fluid 2 h
after i.c.v. administration of sAβ or vehicle in PFC, no more than
10% difference among sample was found, then the data obtained
from four consecutive samples per animal were averaged, and
mean value from n animals per group was determined.
As shown in Figure 6, extracellular levels of glutamate were
significantly increased in PFC of sAβ-treated animals compared
to control (t-test: P < 0.05).
DISCUSSION
Our results show for the first time that an acute i.c.v. injection
of sAβ peptide, during the process of long term memory forma-
tion, did not disrupt memory storage but, when the information
was properly stored, it acutely interfered with its consolida-
tion/retrieval, and such effect was prevented by NMDA receptor
inhibition. The possibility to mimic the detrimental action of sAβ
peptides in vivo provides a very interesting tool for understanding
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FIGURE 2 | (A) Exploratory activity of novel and familiar objects during T2,
(B) discrimination index and (C) total exploration time in NOR1 test.
Animals received i.c.v. injection of vehicle (5 µl; sham) or sAβ (4 µM, 5 µl)
2 h before training (T1) and tested 1 min after (T2). Data are expressed as
mean ± SEM of total time in s (n = 8 sham; n = 9 sAβ-treated group).
(Two-way RM ANOVA followed by Bonferroni’s multiple comparisons test
***P < 0.0001 vs. familiar object in sham group and *P < 0.05 vs. familiar
object in sAβ-treated group).
their mechanism of action. However, since a single species of
Aβ is responsible for the complex dysregulation of intracellular
signaling pathways that takes place in Aβ-mediated effects, it is
reasonable to expect that distinct Aβ assemblies may differentially
affect specific pathways underlying synaptic dysfunction (Mucke
and Selkoe, 2012). Moreover, given that Aβ oligomeric species
act on independent targets, it seems of particular interest to
understand the biological effects of a particular assembly form.
FIGURE 3 | (A) Exploratory activity of novel and familiar objects during T2,
(B) discrimination index and (C) total exploration time in NOR2 test.
Animals received i.c.v. injection of vehicle (5 µl; sham) or sAβ (4 µM, 5 µl)
2 h before training (T1) and tested 24 h later (T2). Data are expressed as
mean ± SEM of total time in s (n = 6 sham; n = 12 sAβ-treated group).
(Two-way RM ANOVA followed by Bonferroni’s multiple comparisons test
***P < 0.001 vs. familiar object; t-test *P < 0.05 vs. sham).
Unlike Aβ assemblies purified from brain’s patients, commercial
available Aβ fragments are considered useful tools as they are
chemically defined, and can be easily characterized, from a struc-
tural point of view, by using several techniques, ranging from
western blot (Jin et al., 2011) to nuclear magnetic resonance (Yu
et al., 2009) and electrophoresis (Wiltfang et al., 1997). However,
one of the best and most informative technique is atomic force
microscopy (AFM; Kowalewski and Holtzman, 1999; Balducci
et al., 2010), which provides a high-resolution image at the
molecular level revealing details of protein structures. By using
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FIGURE 4 | (A) Exploratory activity of novel and familiar objects during T2,
(B) discrimination index and (C) total exploration time in NOR2 test.
Animals received i.c.v. injection of vehicle (5 µl; sham) or sAβ (4 µM, 5 µl)
2 h before training (T1) and tested 24 h later (T2). Memantine (5 mg/kg) was
given immediately after a 10 min training. Data are expressed as mean ±
SEM of total time in s (n = 8 sham/M; n = 8 sAβ/M). (Two-way RM ANOVA
followed by Bonferroni’s multiple comparisons test **P < 0.01 and *P <
0.05 vs. familiar object).
AFM, we precisely characterized sAβ fragments and, to further
confirm the conformation of the peptide, we used the transmis-
sion electronic microscopy (TEM); both techniques enabled us to
feature the types of sAβ fragments, with no fibrils being present
in the injected solution (our unpublished data, Campagna et al.,
2011). Moreover, in our study, the use of defined synthetic sAβ
preparations removed unknown factors, which can be present in
cells and brain extracts or cerebrospinal fluid that could mask
or exacerbate their effects. From a behavioral point of view and
FIGURE 5 | (A) Exploratory activity of novel and familiar objects during T2,
(B) discrimination index and (C) total exploration time in NOR2 test.
Animals received i.c.v. injection of vehicle (5 µl; sham) or sAβ (4 µM, 5 µl)
2 h before training (T1) and tested 24 h later (T2). Memantine (5 mg/kg) was
given 30 min before training. Data are expressed as mean ± SEM of total
time in s (n = 6 sham/M; n = 6 sAβ/M). (Two-way RM ANOVA followed by
Bonferroni’s multiple comparisons test ***P < 0.01 vs. familiar object,
t-test *P < 0.05 vs. sham).
to explore the effects of sAβ on memory, we chose the NOR
test. This behavioral paradigm has become a widely used model
for the investigation in memory alterations. It is usually used
to measure recognition memory, which is heavily impaired in
AD. This test represents a simple and reproducible behavioral
assay, which relies primarily on rat’s innate and spontaneous
exploratory behavior in the absence of reinforcement or the
need for stressful elements. It has been demonstrated that the
NOR test allows to study either short or long term memories.
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FIGURE 6 | Quantitative analysis of basal extracellular glutamate levels
in PFC of rats 2 h after i.c.v. injection of vehicle (5 µL; sham) or sAβ
(4 µM, 5 µl). Data are expressed as mean ± SEM (n = 6 sham, n = 4 sAβ).
(Student t-test *P < 0.05).
In particular, results of NOR paradigm are influenced by the
manipulation of the amount of time required for the intertrial
interval (Taglialatela et al., 2009). In the present study, two
variants of NOR test were used to investigate the effects of sAβ
on short and long term memory. During the NOR1, animals
were exposed to the test phase 1 min after the familiarization
phase. During testing, a novel object needs to be detected and
encoded, while a familiar object needs to be updated. In these
experimental conditions, rats treated with sAβ 2 h before behav-
ioral investigation, exhibited normal performance during the test
and remained cognitively intact. In these animals, when novel
and familiar stimuli were present together, the novel stimulus
was more explored until novelty was lost. Indeed, the preference
for the novel object means that presentation of the familiar one
was already present in their memory, indicating that during the
NOR1, sAβ did not affect this short term memory. Then, in our
animal model, sAβ injected i.c.v. before the acquisition of the
information (familiarization phase) did not affect the informa-
tion being encoded. These results confirmed our previous inves-
tigations where we demonstrated that, in the context of normal
levels of general motor activity, sAβ did not alter the ability of
rats to differentiate between a familiar and a novel object, in
a short term memory test, even when the test was performed
7 days after i.c.v. injection (Colaianna et al., 2010). However,
memory relies on a set of processes by which information is
encoded, consolidated, and retrieved. In addition, when a certain
memory is recovered in the presence of novelty, it is set into an
unstable state, during which its retention can be either enhanced
or impaired.
Over the next hours, memories require stabilization to persist
and are consolidated over time into long term memories, and
once in that state, they remain fixed. This processing memory
is involved in the reorganization of the already formed mem-
ories, allowing then incorporation of new information (Clarke
et al., 2010). Based on this, although the NOR1 behavioral
protocol could not permit to assess sAβ effects on consolida-
tion or recall processes, it seems that the peptide does not
affect short term memory. Thus, we modified the retention
interval, which is the amount of time the rat must retain the
memory of the two identical objects presented during the training
session prior to the testing session. Thus, the rat’s ability to
acquire the object recognition memory by using an intertrial
interval of 24 h was tested. Interestingly, in these experimental
conditions (NOR2), when sAβ-treated rats were re-exposed to
either the familiar or the novel object, they did show signif-
icant difference between groups in time spent for exploration
of both objects, meaning that animals were unable to remem-
ber the object previously investigated. These data suggest that,
when the information was properly encoded, as demonstrated
by using the NOR1 task, sAβ did not disrupt memory stor-
age but acutely interfered with its consolidation/retrieval. Actu-
ally, disruption of memory formation results from interference
with key biological mechanisms underlying the stabilization of
memory.
Depending on the time when the disturbance occurs in this
biological activity, a specific phase of memory formation might be
influenced. The delay-dependent decrease in memory recognition
we observed might result from a decay in memory of the familiar
object. Thus, one hypothesis that could account, at least in part,
for these results is that sAβ was able to induce anterograde amne-
sia, namely the inability to learn new information, although this
hypothesis requires further investigation. It is known that patients
with this form of amnesia preserve intact the capacity to retain
small amounts of information over short periods of time but are
dramatically impaired in their ability to form long-term mem-
ories (Markowitsch and Staniloiu, 2012). Thus, in our animal
model, a single i.c.v. injection of sAβ impaired memory consoli-
dation/retrieval within 24 h, suggesting that the peptide interferes
with the synaptic activity, which is essential for the stabilization of
new memories (Mayford et al., 2012). Indeed, if the memory was
properly consolidated in the rats, then it should have been retriev-
able during the test phase, as seen in controls. Thus far, there are
only few in vivo studies of the involvement of sAβ in memory
alterations in rats (Cleary et al., 2005; Lesné et al., 2006; Poling
et al., 2008; Shankar et al., 2008). As demonstrated by Lopez-
Ramos et al. (2012), SAMP8 mice showing cognitive dysfunctions
probably related to amyloid aggregates have significant deficits in
the acquisition phase of the object recognition test. Our results
seem in some contrast to the evidence reported in AD patients,
who are unable to store newly acquired information but preserve
old memories, especially in early-stage of the disease. However,
based on our results, it cannot be excluded that, in AD patients,
the old events have occurred before the brain damage and this
made possible the retention of retrieved material which has been
successfully consolidated and stored into old memories for such
events. On the other hand, in regard to the ability of sAβ to impair
memory, possibly by inhibiting LTP, it has been hypothesized that
the peptide may play a role in the process of physiological forget-
fulness (Hasegawa, 2007). Interestingly, pathologies in which this
physiological process seems to be impaired, such as posttraumatic
stress disorder, are linked to increased risk of cognitive decline and
AD-associated dementia (Weiner et al., 2014). The mechanism
by which sAβ peptide induces consolidation/retrieval impairment
is not clear yet, but the present results raise the possibility
that the modulation of glutamatergic neurotransmission could
be involved. Indeed, memory processing requires glutamatergic
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receptor activation (Kandel et al., 2014). It has been recently
demonstrated that sAβ dimers extracted from AD cortex induced
their effects by perturbing glutamatergic synaptic transmission,
being mGlu receptors required for the induction of LTD, while
NMDA receptors were needed for spine loss (Shankar et al.,
2008). Moreover, an association of Aβ peptides with several
receptors has been described in literature, and these receptors
might act as substrates for the Aβ-mediated detrimental effects
leading to the aforementioned functional cognitive alterations.
Among others, glutamatergic receptors have been proposed as
mediating the effect of Aβ on synaptic plasticity and memory
(Klyubin et al., 2008; Ferreira and Klein, 2011). Consistent with
this, sAβ enhances NMDA receptor agonist-induced delayed cog-
nitive dysfunction (Dornan et al., 1993; Nakamura et al., 2006).
Soluble Aβ has also been found to enhance glutamate release
from microglia (Noda et al., 1999), isolated brain nerve terminals
(Bobich et al., 2004) and brain slices (Arias et al., 1995; Chin
et al., 2007; Puzzo et al., 2008; Kabogo et al., 2010). Accordingly,
in our experimental conditions, we found a significant increase
in glutamate release in PFC of treated rats. Such result is of
particular interest in our research considering that it has been
reported that PFC plays a crucial role in object recognition as well
as in memory consolidation (Ragozzino et al., 2002; Xiang and
Brown, 2004). Moreover, blocking synthesis of protein or NMDA
receptors resulted in failure of consolidation of memory 24 h after
familiarization phase (Akirav and Maroun, 2006). On the other
hand, several reports suggest that NMDA receptors were closely
associated with Aβ oligomer binding sites on neurons (De Felice
et al., 2007; Lacor et al., 2007; Dewachter et al., 2009). Then, given
the role of NMDA receptors in Aβ-induced synaptic dysfunction,
we directly tested the hypothesis that a NMDA receptor-blocking
dose of memantine (5 mg/kg i.p.), clinically used to treat AD,
could counteract the consolidation/retrieval failure observed in
sAβ-treated rats. Memantine is an NMDA receptor open channel
blocker, which has been found to act with a low-to-moderate
affinity at therapeutic concentrations (Lipton, 2007; Parsons and
Gilling, 2007; Parsons et al., 2007). Unlike many high affin-
ity antagonists (Ikonomidou and Turski, 2002), it preferentially
blocks excessive or inappropriate activation of NMDA receptors,
while leaving physiological NMDA receptor-mediated activity
unaffected (Lipton, 2007; Parsons and Gilling, 2007; Parsons
et al., 2007). In vitro and in vivo studies using animal models
of neurodegenerative diseases and stroke showed that meman-
tine protects neurons from NMDA receptor-mediated excitotoxic
damage (De Felice et al., 2007; Xia et al., 2010). Mechanistically,
we found that acute treatment with NMDA receptor blocking
dose of memantine can prevent the consolidation/retrieval fail-
ure, caused by exogenous acute sAβ administration. Accordingly,
these results confirm previous data showing that sAβ oligomers
directly activate NMDA receptors (Texidó et al., 2011). It should
be noted that the observed effects of memantine in the present
study were achieved at concentrations that are considered clin-
ically relevant, leading to plasma levels of 1.2 µM, and that
memantine has been shown to be active as an NMDA receptor
antagonist at this concentrations as well (Misztal et al., 1996;
Danysz and Parsons, 2003). Of note, when memantine was given
before encoding memory process, animals remained cognitively
impaired, suggesting that, in presence of exogenous sAβ, excessive
NMDA activation, due to increased glutamate release, is deleteri-
ous only during the consolidation/retrieval phase. On the other
hand, it has been demonstrated that, if acute administration is
used, than memantine 5 mg/kg i.p., is the maximal therapeutically
relevant dose for 30–60 min time point, although age, strain,
gender and health status of rats should also been considered,
since they can influence pharmacokinetic parameters consider-
ably (Danysz et al., 1997). In addition, it has been reported that
such dose took the peak serum concentration at ca. 30 min,
which correspond to the upper limit of dose seen in patients and
volunteers after therapeutic dose of memantine (Zoladz et al.,
2006). It is important to underline that, under our experimental
conditions, memantine, given alone or co-administered with sAβ
had no effect on locomotor (data not shown) and exploratory
activities. Our findings are in good agreement with clinical
results showing that memantine treatment improves cognitive
performance in AD patients (Peskind et al., 2006). In addition,
memantine administration has been previously associated to an
improvement in cognitive performance in animal models of AD,
characterized by amyloid deposition (Nakamura et al., 2006;
Martinez-Coria et al., 2010). The novelty of our findings relies on
the evidence that memantine was effective in the absence of actual
Aβ deposits. In this regard, we have previously demonstrated,
by immunofluorescence experiments, that after 48 h from i.c.v.
injection, sAβ peptide was no longer detectable in the ventricular
space (Trabace et al., 2007). Then, it seems likely from our results
that sAβ-induced impairment of consolidation/retrieval of long
term memories and memantine ability to restore cognitive deficits
might precede the development of insoluble amyloid plaque cores
and then neurodegeneration. Our data also indicate that, in this
model, acute sAβ-mediated memory impairment is not depen-
dent on a persistent neurodegenerative phenomenon and can be
rescued, suggesting that early targeting sAβ-induced alterations
might lead to the recovery of cognitive impairment.
CONCLUSIONS
Our study showed that sAβ was able to acutely alter consolida-
tion/retrieval of long term memory, and this effect suggesting
that early targeting sAβ-induced alterations might lead to the
recovery of cognitive was prevented by the use of a clinically
relevant dose of memantine. This evidence suggests that sAβ-
induced consolidation/retrieval failure might contribute to the
memory impairment observed in AD even in the early stages
of disease. Moreover, the present findings further our knowl-
edge on the possibility of prevent cognitive deficits with NMDA
receptor inhibition in an acute rat model of i.c.v. sAβ injection.
Besides, using the acute animal model to explore the mechanism
of action of sAβ, it might also be helpful to assess the efficacy
of novel therapeutic approaches directly aimed at this soluble
species.
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